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Gordon Brown’s agenda for the NHS
The government has willed the ends, but will it provide the means and 
mechanisms for effective prevention and improved outcomes?
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Gordon Brown’s first major speech on the National 
Health Service was spun to the media as a populist 
plea for health checks and screening programmes 
to be made widely available. In reality, it offered a 
reflective and wide ranging assessment of the state 
of the NHS in England in its 60th year and a broad 
indication of the future direction of reform.1 2 In the 
process, the speech gave the clearest indication yet of 
the prime minister’s agenda for health policy.
At the heart of this agenda is the need for the ben-
efits of medical advances to be made available in the 
NHS. In words that echoed Harold Wilson’s advo-
cacy of the white heat of technology in the 1960s, 
Brown praised the progress already made through 
developments in clinical research, and welcomed 
the establishment of Europe’s largest medical science 
centre in London. He also indicated his willingness 
to accept increased concentration of services and 
hospital closures where there was evidence that this 
would deliver improved outcomes, even if this risked 
unpopularity with the public.
The speech emphasised the importance of the pre-
vention of illness as well as the treatment of sickness. 
Prevention will be promoted by offering easier access 
to health checks and the provision of screening serv-
ices recommended by the UK National Screening 
Committee. Primary care will be expected to play 
its part, with patients accessing routine tests such as 
blood tests, electrocardiography, and ultrasound in 
general practitioners’ surgeries. Alongside these NHS 
measures, Brown called for promotion of exercise in 
schools, a single labelling system to describe clearly 
the nutritional value of food products, and a more 
active role by employers in improving health in the 
workplace.
The prime minister signalled a renewed commit-
ment to improve the care of people with chronic dis-
eases. Specifically, the NHS will be expected to do 
more to support people to manage their own condi-
tions through a major expansion of the lay led Expert 
Patient Programme3 and, more radically, by extend-
ing to health care the use of the direct payments—per-
sonal health budgets—announced last month for older 
and disabled people to buy personal (mainly social) 
care.4
The speech also underlined the need to match 
increased rights for patients with clearer responsibili-
ties. In an adaptation of John F Kennedy’s aphorism, 
the prime minister argued that patients should ask of 
the NHS “not just . . . what it can do for you but what, 
empowered with new advice, support and informa-
tion, you can do for yourself and your family.” More 
detail will be available later in the year when the 
much trailed NHS constitution is published, which 
will set out the “NHS offer” to the public and clarify 
how the government expects people to take respon-
sibility for managing their own health.
Another key theme was the government’s com-
mitment to improve access to primary care services. 
As well as the familiar refrain that practices should 
extend opening hours in the evenings and weekends, 
the prime minister indicated that NHS foundation 
trusts would be allowed to provide primary care in 
future. This opened up the prospect of increased com-
petition in primary care, both from the independent 
sector and from other parts of the NHS—Brown’s 
speech indicated that there would be no “no go” areas 
of reform as further progress is made in extending 
patient choice.
Lastly, the prime minister asserted his view that 
“the NHS is the best insurance system for the long 
term,” with the founding principle that health care 
should be available on the basis of need and not abil-
ity to pay. The importance of public funding is under-
lined by the need to pool risks as medical advances 
offer increased potential to diagnose illnesses, the 
increasing costs of some treatments, and the value of 
these costs being shared to promote equity. 
In setting out the direction of travel for the NHS, 
the speech was much stronger on the government’s 
priorities rather than how these will be achieved. 
The emphasis on prevention is welcome, but will 
more resources be shifted to make these aspirations 
a reality?
Prevention has had numerous false dawns, extend-
ing back at least as far as 1976, and it is not clear 
how the health reform programme in England will 
be more successful than previous efforts in making 
prevention “everybody’s business.”5
More detail is also needed on the plans to improve 
care for people with chronic diseases. Personal health 
budgets may empower some people, but they may 
not be appropriate for people with complex comor-
bidity—the heaviest users of NHS services with the 
greatest need for higher standards of care. Equally 
challenging will be changing the culture of provision 
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of health care to ensure that patients really are seen 
as partners and are genuinely empowered to be active 
participants in care.
These arguments indicate that there is a lacuna in 
the prime minister’s announcements, namely the lack 
of an explicit theory on how to change public services 
like the NHS. Gordon Brown clearly does not share 
Tony Blair’s enthusiasm for the use of markets (a word 
notable by its absence from this speech), but he is yet 
to reveal his alternative. This week’s statement is best 
seen as the beginning of the process of identifying 
a distinctively Brownite agenda for the NHS rather 
than the final word. 
1	 Brown	G.	Speech	on	the	national	health	service.	7	January	2008.	
www.number10.gov.uk/output/Page14171.asp.
2	 White	C.	Prime	minister	promises	raft	of	new	screening	tests.	BMJ	
2008;336:62.	doi:	10.1136/bmj.39454.738912.4E.
3	 National	Health	Service.	Expert	patients	programme.	2007.	www.
expertpatients.nhs.uk/public/default.aspx	.	
4	 Department	of	health.	Putting	people	first:	a	shared	vision	and	
commitment	to	the	transformation	of	adult	social	care.	2007.	http://
www.dh.gov.uk/en/Publicationsandstatistics/Publications/
PublicationsPolicyAndGuidance/DH_081118	.
5	 Department	of	Health	and	Social	Security,	Prevention	and	Health.	
Everybody’s business.	London:	HMSO,	1976.
Three months after the interim report from Sir John 
Tooke’s independent inquiry into Modernising Medical 
Careers (MMC) in the United Kingdom1-3 comes the 
final report.4-6
The interim report was well received—87% of 
respondents to consultation either agreed or strongly 
agreed with the original 45 recommendations. Some 
of these have been slightly tweaked in the final report 
and two new ones have been added—the creation of a 
new oversight body for postgraduate medical educa-
tion and training, and exploration of ways to legally 
offset or compensate for the effects of the European 
Working Time Directive.
For practising doctors the final report’s recommen-
dations for the structure of postgraduate training will 
matter most (see figure on bmj.com). Sir John recom-
mends abandoning run through training for something 
that seems familiar, beginning with a one year post 
that resembles the pre-registration house officer of old, 
followed by three years of core specialist training as a 
registered doctor—a post that resembles the old senior 
house officer grade.
The report argues for the uncoupling of current 
foundation years 1 and 2 (FY1 and 2), which would 
allow universities to guarantee a first medical job to 
their graduates (currently, European Union medi-
cal graduates requiring provisional registration can 
legitimately compete for FY1 positions). The current 
FY2 year would be bundled in with current special-
ist training years 1 and 2 to make up three years of 
core specialist training. The report rates the change as 
“entirely consistent” with the principles of training that 
has a broad based beginning and flexibility, which got 
mysteriously subverted7 somewhere between the chief 
medical officer’s 2002 consultation document Unfinished 
Business: proposals for reform of the senior house officer grade 
and the first MMC report a year later. 
Entry to higher specialist training from core specialist 
training would entail assessments administered several 
times a year by national assessment centres, initially 
introduced on a trial basis for highly competitive spe-
cialties. Shortlisting for structured interviews for higher 
specialist training posts would take into account assess-
ment scores, answers to specialty specific questions, 
and structured CVs.
Successful completion of higher specialist training 
would lead to a certificate of completion of training 
“confirming readiness for independent practice in that 
specialty at consultant level.” The interim report had 
two discrete positions after completion of training—
“specialist” and “consultant”—separated by “optional 
higher specialist exams”. This was understandably 
interpreted as covert support for a subconsultant grade. 
Despite some fancy footwork, the final report doesn’t 
banish that suspicion entirely.
The length of training for general practice would 
be extended to five years—three years of core training 
plus two years as a general practitioner specialist regis-
trar—bringing it in line with training in other developed 
European countries.
The interim report laid many of the problems beset-
ting MMC—including unclear lines of responsibility and 
overemphasis on workforce imperatives—at the door of 
the Department of Health. Sir John now redresses the 
balance by proposing that the chief medical officer is 
made the senior responsible officer for medical educa-
tion and the medical profession’s reference point regard-
ing postgraduate medical education and training.
The chief medical officer would also liaise closely 
with a completely new body, NHS: Medical Education 
England (NHS:MEE), the functions of which would 
include defining the principles underpinning postgrad-
uate medical education and training and holding the 
ring fenced budget for these in England. The new body 
is given a part to play in more than a third of the final 
report’s recommendations.
The mismatch between numbers of applicants and 
available training posts—one of the main causes of jun-
iors’ pain in 2007—is beyond the report’s remit. Last 
year there were 32 649 applicants for 23 247 specialist 
training posts in the UK. F igure 4.17 of the interim 
report shows that the oversupply of applicants (9402) 
almost equals the number of applicants with highly 
skilled migrant programme visas (10 014). This scheme, 
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Preparing health professionals and the public for a flu 
pandemic has been the subject of much research world-
wide, and governments and public health departments 
have published various recommendations over the past 
five years.1-4 One aspect of the clinical management of 
respiratory viruses—namely barrier methods to reduce 
transmission—is assessed in the accompanying system-
atic review by Jefferson and colleagues.5 This review 
found that handwashing and wearing masks, gloves, 
and gowns were effective individually in preventing 
the spread of severe acute respiratory syndrome, and     
even more effective when combined (odds ratio 0.09, 
95% confidence interval 0.02 to 0.35, number needed 
to treat (NNT)=3, 2.66 to 4.97). The incremental effect 
of adding virucidals or antiseptics to normal handwash-
ing to reduce respiratory disease was uncertain.
Because pandemic flu is such a potentially cata-
strophic event, governments worldwide should have 
commissioned such a review many years ago and not 
have left it to the academic community to take the 
lead. The academic community needs to educate gov-
ernments that expert advice is not necessarily the best 
advice. Guidelines should be based on rigorous system-
atic reviews and need to be continuously updated.
Government and international websites such as the 
World Health Organization website on the status of 
pandemic flu (www.who.int/csr/disease/avian_influ-
enza/phase/en/index.html) are of some help in keep-
ing health professionals up to date with the latest 
information. However, regularly updated evidence 
based guidelines containing levels of recommendation 
and, where possible, measures of effectiveness such as 
NNT would be very much more helpful to front line 
clinicians. Guidelines also highlight where the strength 
of the evidence is weak and more research is needed. 
We have an annually updated guideline on the man-
agement of hypertension,6 and it reflects badly on the 
consistency of knowledge translation that one is not 
available for influenza.
The messages distributed by governments about 
how to reduce the spread of respiratory viruses have 
not been shown to be wrong, although some are not 
supported by evidence. Jefferson and colleagues’ 
review will allow the effectiveness of the interventions 
however, is the business of the Home Office and the 
Treasury, and the Treasury is presumably happy to use 
an oversupply of applicants to keep down the pressure 
for salary increases. When the Department of Health 
tried unilaterally to impose additional conditions to the 
scheme, it was swatted down by the appeal court for 
its pains.8 The best that the report can do is to call for 
“a coherent model of medical workforce supply within 
which apparently conflicting policies on self-sufficiency 
and open-borders/overproduction should be publicly 
disclosed and reconciled.”
What are the chances that all 47 of the final report’s 
recommendations will be implemented? The execu-
tive summary concludes that strong agreement with 
the interim report provided “a compelling mandate 
for the implementation of the proposals.” But will the 
government agree? Governments have long found the 
best way to defuse a row is to appoint a suitably quali-
fied member of the great and the good to conduct an 
inquiry. Nothing need actually change once the hoohah 
has blown over.
At the same time as Sir John was putting the fin-
ishing touches to his report, the House of Commons 
select committee on health was taking evidence on 
MMC—from many of the same people Sir John had 
interviewed. Worryingly, it heard that the secretary of 
state for health and chief medical officer had recently 
defended the concept of run through training and were 
going to retain it.9 It seems unlikely that the select com-
mittee’s final recommendations will be identical to Sir 
John’s. And Lord Darzi’s broader review of the National 
Health Service may also consider medical careers. 
Before any other body’s recommendations about 
postgraduate medical education and training are imple-
mented, they must be shown to be superior to those 
that have emerged from Sir John’s meticulous review 
of the topic, conducted with an urgency that befits its 
importance to doctors and patients alike.
1	 Tooke	J.	Aspiring to excellence: findings and recommendations of the 
independent inquiry into Modernising Medical Careers. Interim	report.	
MMC	Inquiry,	2007.	www.mmcinquiry.org.uk.
2	 Eaton	L.	Tooke	inquiry	calls	for	major	overhaul	of	specialist	training.	
BMJ	2007;335:737.	doi:	10.1136/bmj.39363.596273.59.
3	 Delamothe	T.	Modernising	Medical	Careers	laid	bare.	BMJ	
2007;335:733-4.
4	 Tooke	J.	Aspiring to excellence: final report of the independent inquiry 
into Modernising Medical Careers.	London:	MMC	Inquiry,	2008.	www.
mmcinquiry.org.uk.
5	 Kmietowicz	Z.	Tooke	report	wants	government	to	step	back	
from	medical	education.	BMJ	2008;336:61;	doi:	10.1136/
bmj.39455.498600.4E.
6	 Delamothe	T.	The BMJ interview: Sir John Tooke.	2008.	www.bmj.
com/audio/index.dtl.
7	 Madden	GBP,	Madden	AP.	Has	Modernising	Medical	Careers	lost	its	
way?	BMJ 2007;335:426-8.
8	 Dyer	C.	Foreign	doctors	win	high	court	challenge	over	training	places.	
BMJ	2007;335:1009;	doi:	10.1136/bmj.39398.720012.DB.
9	 Crockard	A,	Heard	S,	Hilborne	J,	Wilson	I,	Mehta	R,	Johnston	M.	House	
of	Commons	select	committee	on	health.	Uncorrected transcript 
of oral evidence.	To	be	published	as	HC	25-iii.	www.publications.
parliament.uk/pa/cm200708/cmselect/cmhealth/uc25-iii/
uc2502.htm.
Using physical barriers to reduce the spread of 
respiratory viruses
Handwashing and wearing masks, gloves, and gowns are highly effective
RESEARCH, p 77  
Martin Dawes chair of family 
medicine, Department of family 
Medicine, McGill University, 
Montreal H2W 1S4 
martin.dawes@mcgill.ca
Competing interests: none 
declared.
Provenance and peer review: 
Commissioned; not externally peer 
reviewed.
BMJ 2008;336:55-6
doi: 10.1136/bmj.39406.511817.Be
 
56	 	 	 BMJ | 12 January 2008 | VoluMe 336
EDITORIALS
Joe Collier emeritus professor 
in medicines policy St George’s 
Hospital, University of London, 
SW17 0Re 
jcollier@sgul.ac.uk
Competing interests. JC was a 
specialist advisor to the House 
of Commons health select 
committee during this inquiry, 
as he was for the committee’s 
inquiry into nICe in 2001-2, and 
its inquiry into the influence of the 
pharmaceutical industry in 2005. 
He was also an advisor to the 
office of fair Trading in its 2007 
inquiry into the Pharmaceutical 
Price Regulation Scheme.
Provenance and peer review: 
Commissioned; not peer 
reviewed..
BMJ 2008;336:56-7
doi:10.1136/bmj.39454.496748.80
 
Parliamentary review asks NICE to do better still
out goes the arbitrary funding threshold: in come  nICe “directives”
and the strength of the evidence supporting them to 
be much more explicit; for example, it will be possi-
ble to add numbers needed to treat for handwashing, 
face masks, and gloves to advisory leaflets for health 
professionals.
So how does the review help clinicians in primary 
care? The benefit of washing hands between patients is 
clear (NNT=4), as is wearing masks (NNT=6), wear-
ing gloves (NNT=5), and wearing gowns (NNT=5). So 
practices need to have a stock of gloves, simple masks 
(not necessarily of the advanced N95 make), and gowns. 
Applying all the recommendations described by various 
government guidelines7—such as isolation, segregation, 
transport, and identification of patients, creating emer-
gency telephone lists of staff, and on-call cover when 
staff are sick—may seem daunting to a small practice 
or office. However, the one advantage with influenza, 
compared with more sporadic epidemics such as pertus-
sis, is that the practice plan can be tried, evaluated, and 
modified each year. 
Jefferson and colleagues point out that the quality of 
the trials was highly variable. We do not have enough 
evidence to be certain about many aspects of care for 
patients with suspected influenza—for example, which 
face mask is more cost effective within different health-
care settings. Although 336 trials on influenza have 
been registered on the WHO international clinical trials 
registry, only three trials are about reducing transmis-
sion using distancing (keeping a physical distance from 
patients with suspected disease) or barrier methods. The 
reasons for this include the lack of research capacity and 
funding and an emphasis on drug based treatments. 
Governments should continue to fund research to con-
firm the findings of this review and to investigate other 
areas of uncertainty that it identifies in the management 
of people with suspected influenza. 
1	 WHO.	WHO strategic action plan for pandemic influenza 2006–2007 
(WHO/CDS/EPR/GIP/2006.2).	2006.	www.who.int/csr/resources/
publications/influenza/WHO_CDS_EPR_GIP_2006_2c.pdf.
2	 National	Health	Service.	UK Health Departments’ influenza pandemic 
contingency plan.	2005.	www.dh.gov.uk/prod_consum_dh/
groups/dh_digitalassets/@dh/@en/documents/digitalasset/
dh_4104437.pdf.
3	 American	College	of	Physicians,	Barnitz	L,	Berkwits	M.	The	health	care	
response	to	pandemic	influenza.	Ann Intern Med	2006;145:135-7.
4	 Fiore	AE,	Shay	DK,	Haber	P,	Iskander	JK,	Uyeki	TM,	Mootrey	G;	Advisory	
Committee	on	Immunization	Practices	(ACIP),	Centers	for	Disease	
Control	and	Prevention	(CDC).	Prevention	and	control	of	influenza.	
Recommendations	of	the	Advisory	Committee	on	Immunization	
Practices	(ACIP),	2007.	MMWR Recomm Rep	2007;56(RR-6):1-54.
5	 Jefferson	T,	Foxlee	R,	Del	Mar	C,	Dooley L, Ferroni E, HewakB, et	 	 	 	 	 	 	
al.	Physical interventions to interrupt or reduce the spreadof	 	 	 	 	 	 	 	 	
respiratory	viruses:	systematic	review.	BMJ	2008doi:	 	10.1136/
bmj.39393.510347.BE.
6	 Khan	NA,	Hemmelgarn	B,	Padwal	R,	Larochelle	P,	Mahon	JL,	Lewanczuk	
RZ,	et	al.	The	2007	Canadian	hypertension	education	program	
recommendations	for	the	management	of	hypertension:	part	2—
therapy.	Can J Cardiol	2007;23:539-50.
7	 Department	of	Health.	Infection control training material.	2007.	www.
dh.gov.uk/en/PandemicFlu/DH_078752.
On Wednesday 9 January 2008, the House of Commons 
health select committee published the report of its 
 second inquiry into the National Institute for Health 
and Clinical Excellence (NICE).1 The committee’s first 
inquiry into NICE was published six years ago,2 just 
three years after the institute’s launch. Much has hap-
pened since the initial inquiry. The institute is now 
well established and is a core policy driver within the 
National Health Service in England and Wales (its remit 
does not cover Scotland), and we know much more 
about how it operates. Moreover, the working environ-
ment of the institute has changed with, for instance, the 
publication of the Cooksey report on funding for health 
research in the United Kingdom,3 the introduction of 
legislation making NICE technology appraisals essen-
tially compulsory,4 the involvement of the courts in a 
legal challenge to NICE,5 and most recently the Office 
of Fair Trading’s critical review of how brand name 
drugs are priced in the UK through the Pharmaceutical 
Price Regulation Scheme (PPRS).6
All these and more have been embraced in this 
new inquiry, for which members visited equivalent 
bodies to NICE in Canada, France, and Scotland; 
took oral evidence from 31 witnesses; and received 
124 written submissions. The committee’s report 
 contains 32 recommendations, many of which are 
far reaching and reflect the work of a particularly 
effective inquisitorial team.
The report highlights certain disappointments—for 
example, the failure of NICE to implement some of 
the committee’s recommendations made in 2002, such 
as making technology appraisals available at the time 
of drug launches. And the report is critical of the way 
ministers have tried to influence decision making by 
NICE. At the same time the committee recognises 
that NICE now plays a vital role in determining NHS 
health policy and that this role is going to become 
“more important and demanding.”
Four particularly notable themes emanate from the 
recommendations, and these relate primarily to the 
institute’s work on technology appraisals of drugs. 
Firstly, the committee calls for greater clarity in NICE’s 
decision making processes. The report recommends 
more communication with stakeholders, a clarification 
of the institute’s role as a rationing body, and a change 
in terminology so that compulsory advice given in tech-
nology appraisals is referred to as a NICE directive, 
leaving other advice from the institute to be referred 
to as guidance or guidelines.
Secondly, the committee questions the threshold 
used by NICE when determining whether or not a 
new drug should be made available in the NHS. As a 
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Managing severe pneumonia in children in  
developing countries
Increasing resistance to first line antibiotics means recommendations  
need changing
Despite advances in our understanding of the epide-
miology and distribution of deaths from pneumonia,1 
more than 150 million cases of pneumonia still occur 
annually, with almost 2.4 million deaths worldwide. 
Pneumonia is perhaps the most frequent cause of 
death in children under 5, including during the new-
born period.2 Deaths from pneumonia in children 
have increased in the wake of the HIV epidemic in 
Africa. Most deaths occur early in the course of illness. 
Because severe pneumonia is usually related to bacte-
rial infection, treatment has largely focused on various 
antibiotic strategies.
In the accompanying randomised controlled trial, 
Asghar and colleagues compare the effectiveness of 
injectable ampicillin plus gentamicin or chloram-
phenicol in children aged 2-59 months with severe 
pneumonia (defined by World Health Organization 
criteria).3 The trial took place in inpatient wards in 
tertiary care hospitals in Bangladesh, Ecuador, India, 
Mexico, Pakistan, Yemen, and Zambia. Significantly 
more children failed treatment with chloramphenicol 
at five days (16% v 11%, relative risk 1.43, 95% confi-
dence interval 1.03 to 1.97).
The study is one of a series of recent studies aim-
ing to improve the treatment of childhood pneu-
monia in various settings.4 5 These findings confirm 
that the increasing resistance of common respiratory 
bacterial pathogens like Streptoccoccus pneumoniae and 
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general rule, NICE recommends only new products 
estimated to cost the NHS less than around £30 000 
(€40 000; $59 000) per quality adjusted life year 
(QALY) for use in the NHS. The committee learnt 
that this amount was determined by NICE, does not 
have any basis in hard science, has not changed since 
NICE’s inception, is not related to the NHS budget, is 
almost certainly higher than that which primary care 
trusts use when they consider new drugs, and does not 
take account of key costs such as those borne by car-
ers and social services. The report recommends that a 
body independent of NICE should be established to 
review the threshold and set the levels and ranges that 
the institute uses.
The committee also recommends that NICE 
appraises all new drugs and that the results of appraisal 
are available at the time of each drug’s launch. These 
more rapid appraisals would, where appropriate, be 
followed by more detailed single or multiple apprais-
als—as happen now—when more research became 
available. Currently, NICE appraises only a propor-
tion of drugs, and seems to concentrate on those that 
are new, expensive, and used in acute medicine and 
secondary care. Moreover, these appraisals are pub-
lished months or years after a drug is marketed. The 
current policy delays the introduction of effective new 
drugs and diverts provision away from older, useful, 
and possibly cheaper measures that have not been 
appraised.
Lastly, the committee is concerned about the qual-
ity of the data available to NICE and how this quality 
is assessed. The data used by NICE, which by and 
large are generated by drug companies and relate to 
published information, are often weak, inadequate, or 
biased—and make reliable decision making difficult. 
The committee wants trial data made available to 
NICE that are more complete, more independent (of 
the drug industry), more relevant to clinical practice, 
and more amenable to the needs of economic evalu-
ation. All the information available to the UK drug 
licensing authority should also be available to NICE.
The Department of Health has three months to 
respond to the report. All of the committee’s recom-
mendations are challenging, but it is those relating to 
the timing and breadth of the technology appraisals 
that would have the widest implications; if adopted 
they would inevitably reduce the amount we spend 
on drugs and temper the influence the drug industry 
has on clinical practice.7 Such changes would also have 
an important bearing on the proposed reforms to the 
Pharmaceutical Price Regulation Scheme, in which 
drug prices would be negotiated at launch for each 
drug by an independent commission using evidence 
of the product’s perceived clinical value, including evi-
dence from NICE.8 
1	 National	Institute	for	Health	and	Clinical	Excellence.	First report of 
the Health Committee 2007-2008. HC27-I.	London:	Stationery	Office,	
2008.
2	 National	Institute	for	Clinical	Excellence.	Second report of the Health 
2001-2002. HC515-I.	London:	Stationery	Office,	2002.
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Haemophilus influenzae to first line antibiotics, such as 
co-trimoxazole and chloramphenicol, means that rec-
ommendations for treating suspected and confirmed 
pneumonia need to be changed.
Several limitations must be kept in mind before gen-
eralising these findings to the treatment of all children 
with very severe pneumonia. The study was restricted 
to children older than 2 months and might not apply 
to a large proportion of newborns and young infants 
who may have a different cause of pneumonia. Chil-
dren with empyema or overt pneumatoceles (sugges-
tive of possible Staphylococcus aureus infection) were 
excluded. Similarly, children with wheezing were not 
included, which potentially limits the applicability of 
these findings to children with secondary infections 
related to infection with respiratory syncytial virus or 
other viruses.6
Given that most deaths from pneumonia occur early 
in the course of the illness, health workers using the 
integrated management for childhood illness guidelines 
need to have clear algorithms for triage, stabilisation 
of children, and initiation of antibiotics. The antibi-
otic regimens for treating non-severe, severe, and very 
severe pneumonia should therefore form a continuum 
that is easy for health systems to implement and moni-
tor on a large scale.
Despite the above limitations, given the increas-
ing rates of drug resistance in common bacteria 
that cause pneumonia—such as Streptococcus pneumo-
niae and Haemophilus influenzae7—the current study 
 supports the switch to more effective antibiotics. 
However, the combination of ampicillin and 
 gentamicin may not be the best choice for develop-
ing countries. The need for multiple doses when 
using this combination may cause problems and 
lead to reduced adherence. The combination has 
limited coverage against Staphylococcus aureus, and 
there are legitimate concerns about the spectrum of 
pathogens that it covers. The spectrum of respira-
tory infections may have changed in regions where 
Haemophilus influenzae type B vaccine or the new 
pneumococcal conjugate vaccines have been intro-
duced to include infections with non-vaccine strains 
as well as Gram negative pathogens.
The growing HIV epidemic in Africa has also 
altered the epidemiology and spectrum of lower res-
piratory tract infections in infected children. Cytome-
galovirus, Pneumocystis jiroveci, and multi-drug resistant 
non-typhoidal Salmonella are now well known to cause 
pneumonia in children in Africa.8 Acute pulmonary 
tuberculosis may also present with features suggestive 
of severe pneumonia and must be kept in mind in 
susceptible populations.
It may be better to use once daily injectable cepha-
losporins such as ceftriaxone or fluoroquinolones 
for treating children with very severe pneumonia 
who require hospital admission or observed ambu-
latory therapy.9 However, the blanket use of sec-
ond line antimicrobial agents in pneumonia makes 
the emergence of future resistance more likely, so 
tighter objective criteria are needed for diagnosing 
severe or very severe pneumonia. Many viral lower 
 respiratory tract infections present with tachypnoea 
and chest recessions, and it may be difficult to distin-
guish them from bacterial infections on clinical criteria 
alone.10 Although recent studies do not indicate a 
good correlation between radiological results and 
clinically defined pneumonia,11 the use of portable 
pulse oximetry may help triage children for hospital 
admission and additional treatment, such as oxygen 
and injectable antibiotics.12 This approach needs to 
be validated in studies of appropriate diagnostic tools, 
including newer molecular methods that enable viral 
and bacterial infections (or combinations of the two) 
to be identified.
In the long term, the most cost effective way to 
reduce childhood mortality from pneumonia is to 
scale up effective evidence based preventive strategies. 
These strategies include promoting effective childhood 
immunisations (especially against measles, invasive 
Haemophilus influenzae type B, pneumococcal infec-
tions, and possibly influenza), improving environmen-
tal conditions through clean water and sanitation, and 
reducing indoor air pollution. In addition, improving 
nutrition at a population level may reduce intrauterine 
growth retardation and deficiencies in micronutrients, 
such as zinc and vitamin A. The challenge is to make 
this happen on a large scale.
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